PCM
BHVN

Prelude Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Prelude Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-35,549
Closed -$5.37M – 1960
2022
Q3 		$5.37M Sell
35,549
-15,812
-31% -$2.34M 0.19% 78
2022
Q2 		$7.48M Buy
+51,361
New +$6.56M 0.21% 60
2020
Q3 		– Sell
-2,128
Closed -$156K – 2647
2020
Q2 		$156K Buy
+2,128
New +$113K 0.01% 812
2020
Q1 		– Sell
-4,581
Closed -$249K – 2353
2019
Q4 		$249K Buy
4,581
+3,447
+304% +$171K 0.01% 787
2019
Q3 		$47K Sell
1,134
-15,735
-93% -$665K ﹤0.01% 1186
2019
Q2 		$739K Buy
16,869
+8,266
+96% +$466K 0.04% 418
2019
Q1 		$443K Buy
+8,603
New +$372K 0.03% 525
2018
Q4 		– Sell
-211
Closed -$8K – 2449
2018
Q3 		$8K Buy
+211
New +$7.76K ﹤0.01% 1565

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Prelude Capital Management's BHVN Position: Q4 2022 in Review

Prelude Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 35,549 shares — an estimated $5.37M sold.

Prelude Capital Management first reported a position in BHVN in Q3 2018 and held it in 8 quarters. The position peaked at $7.48M in Q2 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Prelude Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Prelude Capital Management sold 35,549 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $5.37M.
  • Prelude Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2018 and held it in 8 quarters.
  • Prelude Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $7.48M in Q2 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Prelude Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.